Preclinical studies have demonstrated the efficacy of BRD9 inhibition in suppressing tumor growth, enhancing the sensitivity of cancer cells to chemotherapy, and modulating immune responses in inflammatory conditions. This evidence concerns the gene BRD9 and cancer.